This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
by Zacks Equity Research
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
by Zacks Equity Research
Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.
Top Stock Reports for Merck, Philip Morris & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
by Zacks Equity Research
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
by Zacks Equity Research
Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
by Zacks Equity Research
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
by Zacks Equity Research
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
by Zacks Equity Research
Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEY
Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.